Unknown

Dataset Information

0

Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPAR?) Modulation by Functional Selective Ligands.


ABSTRACT: The nuclear receptor PPAR? regulates adipogenesis and plays a central role in lipid and glucose homeostasis, and is the molecular target of the glitazones (TZDs), therapeutics used to treat insulin resistance and type-2 diabetes (T2D). Although the TZDs, which are PPAR? agonists, demonstrated robust clinical efficacy in T2D, their use has been hampered by an array of untoward side effects. Paradoxically, partial agonists (e.g. MRL24), antagonists (e.g. SR1664), and inverse agonists (e.g. SR10171 and SR2595), possess similar insulin-sensitizing efficacy as the TZDs in obese diabetic mice. Given the unique pharmacology of these modulators, we sought to identify the components of the PPAR? transcriptional complex that is regulated by these ligands. To achieve this, we employed subcellular fractionation of adipocytes combined with either trapping of the receptor complex on biotinylated DNA oligonucleotide, or classical immunoprecipitation. Tandem mass spectrometry analysis revealed unique, partially overlapping, compound- and subcellular compartment-specific complexes. Components of these interactomes are putative coregulators of PPAR?. Interestingly, complexes isolated in the cytosol contain sets of proteins involve in cellular assembly and extracellular matrix. Furthermore, the interactome observed for cytosolic non-DNA bound receptor was distinct from that observed from nuclear chromatin associated PPAR?, suggesting cellular compartment-specific roles for this receptor.

SUBMITTER: Lam VQ 

PROVIDER: S-EPMC5724174 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.

Lam Vinh Q VQ   Zheng Jie J   Griffin Patrick R PR  

Molecular & cellular proteomics : MCP 20170929 12


The nuclear receptor PPARγ regulates adipogenesis and plays a central role in lipid and glucose homeostasis, and is the molecular target of the glitazones (TZDs), therapeutics used to treat insulin resistance and type-2 diabetes (T2D). Although the TZDs, which are PPARγ agonists, demonstrated robust clinical efficacy in T2D, their use has been hampered by an array of untoward side effects. Paradoxically, partial agonists (<i>e.g.</i> MRL24), antagonists (<i>e.g.</i> SR1664), and inverse agonists  ...[more]

Similar Datasets

| S-EPMC5666307 | biostudies-literature
| S-EPMC3267299 | biostudies-literature
| S-EPMC4395532 | biostudies-literature
| S-EPMC10466243 | biostudies-literature
| S-EPMC6494719 | biostudies-literature
| S-EPMC3215401 | biostudies-literature
| S-EPMC6752943 | biostudies-literature
| S-EPMC2189817 | biostudies-other
| S-EPMC5297650 | biostudies-literature
| S-EPMC26842 | biostudies-literature